A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH
NCT ID: NCT03818607
Last Updated: 2023-05-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
42 participants
INTERVENTIONAL
2019-01-22
2022-07-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03500549
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
NCT00098280
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
NCT00130000
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04702568
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT01194804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T (ABP 959) / R (eculizumab)
ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
ABP 959
intravenous infusion
Eculizumab
intravenous infusion
R (eculizumab) / T (ABP 959)
Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2
ABP 959
intravenous infusion
Eculizumab
intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABP 959
intravenous infusion
Eculizumab
intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Historical diagnosis of PNH.
* Administration of eculizumab for ≥ 6 months and currently receiving 900 mg of eculizumab.
* Hemoglobin ≥ 9.0 g/dL for at least 6 weeks before randomization.
* Lactate dehydrogenase \< 1.5 × the upper limit of normal at screening.
* Platelet count ≥ 50 × 10\^9/L.
* Absolute neutrophil count (ANC) ≥ 0.5 x 10\^9/L (500/μL).
* Participants must be vaccinated against Neisseria meningitidis.
* Participants must sign an IRB/IEC-approved ICF before participation in any procedures.
Exclusion Criteria
* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure \[New York Heart Association ≥ Class III\], serious uncontrolled cardiac arrhythmia), peripheral vascular disease, cerebrovascular accident, or transient ischemic attack in the previous 6 months.
* Evidence of acute thrombosis (liver Doppler ultrasound of hepatic and portal veins).
* Known to be positive for human immunodeficiency virus.
* Woman who is pregnant or breastfeeding.
* Participant is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or participant is receiving other investigational agent(s).
* Participant has known sensitivity to any of the products to be administered during the study, including mammalian cell-derived drug products.
* History of meningococcal infection.
* Presence or suspicion of active bacterial infection, or recurrent bacterial infection.
* History of bone marrow transplantation.
* Red blood cell transfusion required within 12 weeks before randomization.
* Participant experienced ≥ 2 breakthrough events, (ie, signs and symptoms of intravascular hemolysis, that require dose and/or schedule adjustments of eculizumab) in the previous 12 months before screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Healthcare of Atlanta at Egleston
Atlanta, Georgia, United States
Fakultní Nemocnice Brno
Brno, Jihormoravsky KRAJ, Czechia
Fakultní Nemocnice Olomouc
Olomouc, , Czechia
Fakultní Nemocnice Ostrava
Ostrava-Poruba, , Czechia
Keski-Suomen keskussairaala Jyväskylä
Jyväskylä, , Finland
Päijät-Häme Central Hospital
Lahti, , Finland
Hôpital Privé Sévigné
Cesson-Sévigné, Brittany Region, France
Saint James's Hospital
Dublin, , Ireland
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Forli-cesena, Italy
Azienda Ospedaliera San Gerardo di Monza
Monza, Monza Brianza, Italy
Azienda Ospedaliera S. Croce e Carle Cuneo
Cuneo, , Italy
Azienda USL della Romagna
Ravenna, , Italy
Fondazione Policlinico Universitario Agostino Gemelli
Roma, , Italy
Radboud Universitair Medisch Centrum
Nijmegen, Gelderland, Netherlands
Oslo University Hospital - Rikshospitalet
Oslo, , Norway
Instituto Português de Oncologia do Porto Francisco Gentil
Porto, , Portugal
Univerzitetni klinični center Ljubljana
Ljubljana, , Slovenia
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Universitario La Fe
Valencia, , Spain
Karolinska Universitetssjukhuset - Huddinge
Stockholm, , Sweden
Ege Universitesi Hastanesi - Sağlık Uygulama ve Araştırma Merkezi
Bornova, İzmir, Turkey (Türkiye)
Mersin Universitesi Tip Fakultesi
Mersin, , Turkey (Türkiye)
The Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
King's College Hospital NHS Foundation Trust
London, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kulasekararaj A, Lanza F, Arvanitakis A, Langemeijer S, Chonat S, Tombak A, Hanes V, Cao J, Miller MJ, Colbert A, Shander B, Mytych DT, Chow V, Henary H. Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2024 Nov;99(11):2108-2117. doi: 10.1002/ajh.27456. Epub 2024 Aug 22.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20150168
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.